Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1996 3
1997 1
1998 1
2002 1
2003 1
2004 3
2005 4
2006 4
2007 6
2008 4
2009 9
2010 4
2011 6
2012 12
2013 17
2014 12
2015 21
2016 35
2017 45
2018 39
2019 50
2020 88
2021 113
2022 139
2023 185
2024 260

Text availability

Article attribute

Article type

Publication date

Search Results

967 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Delivery technologies for cancer immunotherapy.
Riley RS, June CH, Langer R, Mitchell MJ. Riley RS, et al. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. Nat Rev Drug Discov. 2019. PMID: 30622344 Free PMC article. Review.
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. ...Here, we discuss these research advances, as …
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug appr …
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
Reck M, Remon J, Hellmann MD. Reck M, et al. J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985920 Review.
For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. ...Although clinical development of immune checkpoint inhibitors with anti-PD-1 and …
For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that ha …
Advances and challenges in the treatment of lung cancer.
Li Y, Yan B, He S. Li Y, et al. Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. Epub 2023 Nov 16. Biomed Pharmacother. 2023. PMID: 37979378 Free article. Review.
In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for the treatment of lung cancer. This article reviews the cutting-edge developments in the nano drug delivery system, molecular targete …
In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for …
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.
Wienke J, Visser LL, Kholosy WM, Keller KM, Barisa M, Poon E, Munnings-Tomes S, Himsworth C, Calton E, Rodriguez A, Bernardi R, van den Ham F, van Hooff SR, Matser YAH, Tas ML, Langenberg KPS, Lijnzaad P, Borst AL, Zappa E, Bergsma FJ, Strijker JGM, Verhoeven BM, Mei S, Kramdi A, Restuadi R, Sanchez-Bernabeu A, Cornel AM, Holstege FCP, Gray JC, Tytgat GAM, Scheijde-Vermeulen MA, Wijnen MHWA, Dierselhuis MP, Straathof K, Behjati S, Wu W, Heck AJR, Koster J, Nierkens S, Janoueix-Lerosey I, de Krijger RR, Baryawno N, Chesler L, Anderson J, Caron HN, Margaritis T, van Noesel MM, Molenaar JJ. Wienke J, et al. Cancer Cell. 2024 Feb 12;42(2):283-300.e8. doi: 10.1016/j.ccell.2023.12.008. Epub 2024 Jan 4. Cancer Cell. 2024. PMID: 38181797 Free PMC article.
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side effects. Since novel and improved immunotherapies may fill this need, we dissect the immunoregulatory interactions in neuroblas …
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side e …
Targeting the gut microbiota for cancer therapy.
Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Fernandes MR, et al. Nat Rev Cancer. 2022 Dec;22(12):703-722. doi: 10.1038/s41568-022-00513-x. Epub 2022 Oct 17. Nat Rev Cancer. 2022. PMID: 36253536 Review.
Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of cancer therapy, most notably immunotherapy and its immune-related adverse effects. The poor response to immunotherapy in patients treated with antibiotics supports this i …
Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of cancer therapy, most notably immunotherap …
Utilizing chemokines in cancer immunotherapy.
Märkl F, Huynh D, Endres S, Kobold S. Märkl F, et al. Trends Cancer. 2022 Aug;8(8):670-682. doi: 10.1016/j.trecan.2022.04.001. Epub 2022 Apr 29. Trends Cancer. 2022. PMID: 35501268 Review.
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for …
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many canc …
Anti-GD2 immunotherapy for neuroblastoma.
Sait S, Modak S. Sait S, et al. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904. doi: 10.1080/14737140.2017.1364995. Epub 2017 Aug 14. Expert Rev Anticancer Ther. 2017. PMID: 28780888 Free PMC article. Review.
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving surviva …
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions t …
Nanomedicine in cancer therapy.
Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Fan D, et al. Signal Transduct Target Ther. 2023 Aug 7;8(1):293. doi: 10.1038/s41392-023-01536-y. Signal Transduct Target Ther. 2023. PMID: 37544972 Free PMC article. Review.
Cancer remains a highly lethal disease in the world. Currently, either conventional cancer therapies or modern immunotherapies are non-tumor-targeted therapeutic approaches that cannot accurately distinguish malignant cells from healthy ones, giving rise to m …
Cancer remains a highly lethal disease in the world. Currently, either conventional cancer therapies or modern immunotherap …
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.
Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G. Liu C, et al. Nat Nanotechnol. 2022 May;17(5):531-540. doi: 10.1038/s41565-022-01098-0. Epub 2022 Apr 11. Nat Nanotechnol. 2022. PMID: 35410368
We describe a genetically engineered cell membrane nanovesicle that integrates antigen self-presentation and immunosuppression reversal (ASPIRE) for cancer immunotherapy. ...This work presents a powerful vaccine formula that can directly activate both native …
We describe a genetically engineered cell membrane nanovesicle that integrates antigen self-presentation and immunosuppression revers …
967 results